ITOVEBI®

(inavolisib)

ROCHE

HK Reg. No. HK-69042, HK-69043 (30 Mar, 2026)

Composition5:

ITOVEBI® is available as tablets in two dose strengths:

• 3 mg: red and round convex-shaped with an “INA 3” debossing on one side

• 9 mg: pink and oval-shaped with an “INA 9” debossing on one side

Indication5:

ITOVEBI® (inavolisib film-coated tablets), in combination with palbociclib and fulvestrant, is indicated for:

• the treatment of adult women with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment

References

1. HERNEXEOS Hong Kong Prescribing Information. 2. Hong Kong Drug Office. PRIMOVIST SOLUTION FOR INJECTION IN PLASTIC PRE-FILLED SYRINGE 0.25 MMOL/ML 10ML. Available from: https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/159313. [Accessed 21 May 2026]. 3. Hong Kong Drug Office. GADOVIST SOLUTION FOR INJECTION IN PLASTIC PRE-FILLED SYRINGE 1MMOL/ML 5ML. Available from: https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/159484. [Accessed 21 May 2026]. 4. Hong Kong Drug Office. GADOVIST SOLUTION FOR INJECTION IN PLASTIC PRE-FILLED SYRINGE 1MMOL/ML 7.5ML. Available from: https://www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/159485. [Accessed 21 May 2026]. 5. ITOVEBI Hong Kong Prescribing Information.